Scientists are designing molecules, changing cell states and testing ways to restore damaged tissue. Follow the programmes and the evidence they produce.
Discovery can move quickly. Human experiments test whether a treatment does what researchers intended.
Read the mechanism, development history and human evidence.
Life Biosciences
ER-100 brings controlled cellular reprogramming into a Phase 1 study of optic nerve disease. Life Biosciences has announced an interim presentation for 8 October 2026. As of 4 October, those findings have not been presented in the verified sources.
Insilico Medicine
Rentosertib connects AI-assisted target selection and molecular design with published lung-disease trial results. A September 2026 analysis examined ageing clocks in stored samples. The developer also announced first dosing in a larger Phase 3 study; the medicine remains experimental.
Academic collaborations at Memorial Sloan Kettering and Cold Spring Harbor Laboratory
Researchers have engineered T cells to recognise uPAR, a surface protein associated with senescence. Mouse studies test whether clearing these cells improves metabolism and intestinal function.
Broad Institute, MIT and academic collaborators
A mouse study uses liver-directed mRNA to supply immune signals. The research tests a temporary change in immune function.
A first dose, a published result or a programme ending. Each development has a date and a source.
Read the development recordA small placebo-controlled trial reported a liver histology result.
Company announcement schedules a glaucoma-cohort presentation for 8 October, after this dossier's verification date.
Insilico reports the start of dosing in GENESIS-IPF-3, identified as NCT07687459.
Models of cells, designed proteins and the experiments that test their predictions.
A virtual-cell model predicts a measurement after researchers change a cell. Its usefulness depends on which experiment it can predict, which examples it has already seen and whether the prediction survives a new biological context.
Read article
AlphaFold predicts molecular structures, AlphaGenome predicts regulatory measurements from DNA, Evo 2 models genomic sequences and State predicts cellular responses. Each needs a different experimental test.
Read article
An automated laboratory becomes a learning system when measured results determine the next experiments. Cell-free protein synthesis and enzyme engineering show what these systems have achieved, how people contributed and which comparisons remain missing.
Read articleFollow AI biology, immune engineering and attempts to repair or replace damaged cells.
How researchers model cells, predict molecular behaviour, design proteins and choose experiments.
02Changing gene expression and cell state while preserving the function a tissue needs.
03Experiments that remove senescent cells or change the signals they release.
04Replacing lost tissue, growing cells and developing organs that can restore function.
05Getting an experimental treatment to the right cells, with enough control over its activity.
06The tests, endpoints and research frameworks used to judge biological and functional change.
A study can measure a change in a molecule, a tissue or a person’s function. Who was studied, what was measured and how the result was obtained determine what it can tell us.
Programme histories keep published findings alongside company disclosures and trial records. Each source is identified so you can check it yourself.
Read the editorial method